Eleven patients with refractory autoimmune hemolytic anemia (AIHA) were all brought into drug-free remission with CAR T-cell ...

The Pediatric Emergency Medicine and Pediatric Hematology/Oncology divisions at MUSC have joined forces to create and test an algorithm for treating children with sickle cell disease who present to ...

An expert discussed the findings of the COMMANDS trial evaluating Reblozyl’s role in red blood cell transfusion independence for patients with MDS. Reblozyl (luspatercept) has become the new standard ...

Sickle cell anemia, a type of sickle cell disease (SCD), is a genetic condition that affects your red blood cells (RBCs). It affects around 100,000 Americans and is most common in people of African, ...

Reblozyl for anemia in patients with an MDS subset demonstrated positive effects, compared with previous treatments, according to an MDS expert. Treatment with Reblozyl (luspatercept-aamt) was ...

CAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients ...

A 21-year-old man has become the first person in New York—and one of the first in the world—to be cured of sickle cell anemia. A novel form of gene therapy enabled the man to receive a life-changing ...

Anemia affects almost 1 in 4 people worldwide. But while billions of people live with the disease, its signs and symptoms aren’t just part of everyday life. “Anemia is one of the most common global ...

Sickle cell anemia is the world's most common genetic disorder. It causes the red blood pigment hemoglobin to crystallize, ...